by Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has signed a definitive asset purchase agreement to acquire CTP-656 from Concert Pharmaceuticals (Nasdaq: CNCE). CTP-656 is an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has the potential to be used as part of future once-daily combination regimens of CFTR modulators that treat the underlying cause of cystic fibrosis (CF). As part of the agreement, Vertex will pay Concert $160 million in cash for all worldwide development and commercialization rights to CTP-656.
by Oregon State University
Researchers at Oregon State University and Oregon Health & Science University are working on a treatment that holds great promise for improving the lives of cystic fibrosis patients. Cystic fibrosis is a progressive genetic disorder that results in persistent lung infection and afflicts 30,000 people in the U.S., with about 1,000 new cases diagnosed every year.
by Cardiff University - Institute for Compound Semiconductors
Local business leaders across South Wales attended the launch of the new facility, which offers a range of solutions for companies working to develop 21st century technologies. Guests were able to learn more about the refurbished 225 square metre Clean Room facility and the role it plays in assisting businesses across South Wales as part of CS Connected – the world’s first Compound Semiconductor cluster.
by ROBIN A. SMITH @DUKERESEARCH
The last 10 years have seen a surge in the use of tiny substances called nanomaterials in agrochemicals like pesticides and fungicides. The idea is to provide more disease protection and better yields for crops, while decreasing the amount of toxins sprayed on agricultural fields.
by Amanda Gibbs - OHSU
Research team discovers drug compound that stops cancer cells from spreading Via a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body Fighting cancer means killing cancer cells....
by NYU Tandon School of Engineering
An international team of university researchers today reports solving a major fabrication challenge for perovskite cells — the intriguing potential challengers to silicon-based solar cells. These crystalline structures show great promise because they can absorb almost all wavelengths of light. Perovskite solar cells are already commercialized on a small scale, but recent vast improvements in their power conversion efficiency (PCE) are driving interest in using them as low-cost alternatives for solar panels.
by Department of Physics Technical University Munich
A team headed by the TUM physicists Alexander Holleitner and Reinhard Kienberger has succeeded for the first time in generating ultrashort electric pulses on a chip using metal antennas only a few nanometers in size, then running the signals a few millimeters above the surface and reading them in again a controlled manner. The technology enables the development of new, powerful terahertz components.
by Minakem
Minakem’s HPAPI production will be carried out with an Occupational Exposure Limit (OEL) below 0,1μg/m3/8h. This emphasis on Environment, Health and Safety (EHS) reflects Minakem’s more than 20 years’ experience in continuously monitoring and controlling hazardous working environments, marking its leadership in this area.
by The University of Akron
Specifically, Zhu and his research team developed a solid polymer electrolyte that can be used in lithium ion batteries to replace the current liquid electrolyte to improve the safety and performance of lithium batteries.
by Shire PLC
Shire plc, the global biotechnology leader in rare diseases, announced today that the United States Food and Drug Administration (FDA) has approved the company’s first submission for its new plasma manufacturing facility near Covington, Georgia for the production of GAMMAGARD LIQUID® [Immune Globulin Infusion (Human)] 10% Solution, a replacement therapy for primary humoral immunodeficiency (PI).
by Northwestern University
covalent organic frameworks (COFs), were discovered in 2005, but their quality has been poor and preparation methods are uncontrolled. Now a Northwestern University research team is the first to produce high-quality versions of these materials, demonstrate their superior properties and control their growth. The researchers developed a two-step growth process that produces organic polymers with crystalline, two-dimensional structures.
by SLAC
A new experimental method permits the X-ray analysis of amyloids, a class of large, filamentous biomolecules which are an important hallmark of diseases such as Alzheimer’s and Parkinson’s. An international team of researchers headed by DESY scientists has used a powerful X-ray laser to gain insights into the structure of different amyloid samples.
